Orasis Pharmaceuticals has announced the availability of Starter Packs of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% to broaden access for patients seeking a flexible option to manage their presbyopia.

Each Qlosi Starter Pack includes 10 vials, 2 daily doses for 5 days of treatment, along with a patient progress tracker and referral card that are shipped directly to the prescribing eyecare practitioner (ECP) for patient dissemination.

Launched in the United States in April 2025, Qlosi is an FDA-approved eye drop with the lowest effective concentration of pilocarpine. Qlosi's proprietary EyeQ Formulation, the company says, is designed for comfort and to maintain an optimal pupil size, strengthening depth of focus and improving near vision without compromising mean distance or night vision. According to the company, in pivotal phase 3 clinical trials, Qlosi demonstrated a favorable safety profile, with no serious side effects reported.